Trump Ends Medicare Part D Premium Subsidies for Seniors

The Trump administration has confirmed it will end a $3.6 billion subsidy program that helped keep Medicare Part D prescription drug premiums stable, a decision affecting roughly 25 million seniors and disabled Americans enrolled in standalone drug plans. Starting in 2027, most beneficiaries are expected to pay more for their prescription drug coverage, with the Centers for Medicare & Medicaid Services (CMS) allowing the Part D Premium Stabilization Demonstration to expire after the current plan year.

The decision, first reported by The Wall Street Journal and confirmed by CMS on July 28, marks the end of a temporary program established by the Biden administration in 2024. According to The New York Times, the move represents a significant shift in healthcare policy that could ripple through the upcoming midterm elections.

Context: A Bridge Program for a New Benefit Structure

The Part D Premium Stabilization Demonstration was created in response to sweeping changes mandated by the Inflation Reduction Act of 2022. That legislation redesigned the Medicare Part D benefit structure, capped annual out-of-pocket drug costs for beneficiaries at $2,000, and allowed Medicare to negotiate prices for certain high-cost medications. These changes created significant uncertainty for insurers, who lacked claims data under the new framework and faced the prospect of substantial premium spikes.

To bridge this transition, the Biden administration launched the demonstration program in 2024, providing participating prescription drug plans with a monthly subsidy of up to $15 per beneficiary and limiting monthly premium increases to $35. In 2026, the Trump administration reduced the subsidy to $10 per month and raised the premium increase cap to $50. Now, with the program’s elimination, the transition period is deemed complete.

How the Decision Affects Beneficiaries

CMS data indicates that the demonstration provided approximately $3.6 billion to private insurers in 2026 alone, helping hold average standalone Medicare Part D premiums at roughly $36 per month. Without this federal support, the base premium for 2027 is projected at $41.33, though actual costs will vary significantly by plan and geographic region.

According to CMS estimates cited by 24/7 Wall St., the impact on beneficiaries will be uneven but widespread:

• Roughly 25% of enrollees — about 6.25 million people — will see their premiums stay flat or decline in 2027.
• About 30% — approximately 7.5 million beneficiaries — are expected to pay less than $10 more per month.
• The remaining 45% — approximately 11.25 million people — could face increases ranging from $11 to $20 per month, depending on their specific plan and local market conditions.

Overall, approximately 75% of Medicare Part D participants are expected to pay more than they currently do. However, CMS notes that the Inflation Reduction Act still limits annual increases in the base beneficiary premium to 6% through 2029, and low-cost plan options will remain available in most markets.

Administration’s Defense of the Decision

Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, defended the decision on social media, characterizing the subsidy program as a corporate bailout that has outlived its purpose. “We are stabilizing the market so this bailout is no longer needed,” Oz wrote. He added that “premiums will go up by less than $10 for most Medicare recipients, with many even seeing LOWER premiums.”

The administration argues that after several years of operating under the redesigned Part D benefit, insurers now have sufficient claims data to price their plans accurately without taxpayer support. A Trump administration official told ABC News that about half of enrollees will either see a premium increase of less than $10 or a premium decrease, and that most will have plans available at $10 or less. CMS has stated it is “facilitating the Part D program’s return to operating under regular market conditions.”

Political and Market Implications

The end of Part D premium subsidies arrives at a politically charged moment. Beneficiaries will receive their 2027 premium notices this fall, just as campaigning for the 2026 midterm elections intensifies. Healthcare costs have already emerged as a top voter concern following the earlier expiration of Affordable Care Act marketplace subsidies.

The decision also raises questions about the long-term stability of the standalone Part D plan market. KFF (formerly the Kaiser Family Foundation) has previously warned that reduced federal support for standalone prescription drug plans “suggests that Medicare beneficiaries in traditional Medicare who have drug coverage through PDPs could face substantially higher premiums.”

Notably, approximately 31 million Americans receive drug coverage through Medicare Advantage plans, a private-sector alternative for people 65 and older that may be less directly affected by this specific change. Drug manufacturers, meanwhile, remain largely unaffected, as the Part D benefit redesign and negotiated drug pricing provisions continue on their separate tracks.

What to Watch For

As the 2027 plan year approaches, several critical questions remain. Private insurers must now decide how to adjust their pricing without the federal subsidy — whether to absorb some costs or pass them entirely to consumers. The relative cost increase of standalone Part D plans could also accelerate a shift toward Medicare Advantage enrollment.

Congress may face pressure to intervene legislatively, particularly from lawmakers representing states with large senior populations. For now, the Trump administration is betting that its broader drug pricing initiatives — including most-favored-nation deals aimed at lowering the cost of prescription drugs — will help offset the premium increases for beneficiaries over time.